Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors

Wound Repair and Regeneration

Volumn 5, Issue 1, 1997, Pages 23-32

  Yager, Dorne R ^a,b   Chen, Stephen M ^a   Ward, Susan I ^a   Olutoye, Oluyinka O ^a   Diegelmann, Robert F ^a   Cohen, I Kelman ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Wound Healing Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0347725622     PISSN: 10671927     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-475X.1997.50108.x     Document Type: Article

References (55)

1. Lynch SE, Colvin RB, Antoniades HN. Growth factors in wound healing: single and synergistic effects on partial thickness porcine skin wounds. J Clin Invest 1989;84:640-6.
2. Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. J Cell Biochem 1991;45:319-26.
3. Greenhalgh DG, Sprugel KH, Murray MJ, Ross R. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol 1990;136:1235-46.
4. Pierce GF, Mustoe TA, Lingelbach J, Masakowski VR, Gramates P, Deuel TF. Transforming growth factor β reverses the glucocorticoid-induced wound healing deficit in rats. Proc Natl Acad Sci U S A 1989;86:2229-33.
5. Mustoe TA, Purdy J, Gramates P, Deuel TF, Thomason A, Pierce GF. Reversal of impaired wound healing in irradiated rats by platelet-derived growth factor-BB: requirement of an active bone marrow. Am J Surg 1989;158:345-50.
6. Ksander GA, Sawamura SJ, Ogawa Y, Sundsmo J, McPherson JM. The effect of platelet releasate on wound healing in animal models. J Am Acad Dermatol 1990;22:781-91.
7. Werner S, Smola H, Liao X, Longaker MT, Krieg T, Hofschneider PH, Williams LT. The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. Science 1994;266: 819-22.
8. Brauchle M, Fässler R, Werner S. Suppression of keratinocyte growth factor expression by glucocorticoids in vitro and during wound healing. J Invest Dermatol 1995;105:579-84.
9. Andree C, Swain WF, Page CP, Macklin MD, Slama J, Hatzis D, Eriksson E. In vivo transfer and expression of a human epidermal growth factor gene accelerates wound repair. Proc Natl Acad Sci U S A 1994;91:12188-92.
10. McGee GS, Davidson JM, Buckley A, Sommer A, Woodward SC, Aquino AM, Barbour R, Demetriou AA. Recombinant basic growth factor accelerates wound healing. J Surg Res 1988;45: 145-53.
11. Buckley A, Davidson JM, Kamerath GD, Wolt TB, Woodward SC. Sustained release of epidermal growth factor accelerates wound repair. Proc Natl Acad Sci U S A 1985;82:7340-4.
12. Baird A, Walicke PA. Fibroblast growth factors. Med Bulletin 1989;45:438-52.
13. Banda MJ, Knighton DR, Hunt TK, Werb Z. Isolation of a nonmitogenetic angiogenesis factor from wound fluid. Proc Natl Acad Sci U S A 1982;79:7773-7.
14. Cromack DT, Sporn MB, Roberts AB, Merino MJ, Dart LL, Norton JA. Transforming growth factor β levels in rat wound chambers. J Surg Res 1987;42:622-8.
15. Ford HR, Hoffmann RA, Wing EJ, Magee DM, McIntyre L, Simmons RL. Characterization of wound cytokines in the sponge matrix model. Arch Surg 1989;124:1422-8.
16. Grotendorst GR, Soma Y, Takehara K, Charette H. EGF and TGF-alpha are potent chemoattractants for endothelial cells and EGF-like peptides are present at sites of tissue regeneration. J Cell Physiol 1989;139:617-23.
17. Knighton DR, Ciresi K, Fiegel VD, Schumerth S, Butler E, Cerra F. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula. Surg Gynecol Obstet 1990;170:56-60.
18. Chen TL, Bates RL, Xu Y, Ammann AJ, Beck LS. Human recombinant transforming growth factor-β1 modulation of biochemical and cellular events in healing of ulcer wounds. J Invest Dermatol 1992;98:428-35.
19. Robson MC, Phillips LG, Lawrence WT, Bishop JB, Youngerman JS, Hayward PG, Broemeling LD, Heggers JP. The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann Surg 1992; 216:401-8.
20. Steed DL, Malone JM, Goslen JB, Bunt TJ, Holloway GA, Webster MW. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. Diabetes Care 1992;15:1598-604.
21. Atri SC, Misra J, Bisht D, Misra K. Use of homologous platelet factors in achieving total healing of recalcitrant skin ulcers. Surgery 1990;108:508-12.
22. Brown GL, Curtsinger L, Jurkiewicz MJ, Nahai F, Schultz G. Stimulation of healing of chronic wounds by epidermal growth factor. Plast Reconstr Surg 1991;88:189-96.
23. Rasmussen LH, Jensen LT, Avnstorp C, Karlsmark T, Peters K, Horslev-Petersen K. Collagen types I and III propeptides as markers of healing in chronic leg ulcers. A noninvasive method for the determination of procollagen propeptides in wound fluid - influence of growth hormone. Ann Surg 1992;216: 684-91.
24. Davies KJ. Oxidative stress: the paradox of aerobic life. Biochem Soc Symp 1995;61:1-31.
25. Whiston RJ, Hallett MB, Davies EV, Harding KG, Lane IF. Inappropriate neutrophil activation in venous disease. Br J Surg 1994;81:695-8.
26. Rees R, Smith D, Li TD, Cashmer B, Garner W, Punch J, Smith DJ Jr. The role of xanthine oxidase and xanthine dehydrogenase in skin ischemia. J Surg Res 1994;56:162-7.
27. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993;101:64-8.
28. Yager DR, Zhang L-Y, Liang H-X, Diegelmann RF, Cohen IK. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase level and activity compared to surgical wound fluids. J Invest Dermatol 1996;107:743-8.
29. Rogers AA, Burnett S, Moore JC, Shakespeare PG, Chen WYJ. Involvement of proteolytic enzymes - plasminogen activators and matrix metalloproteinases - in the pathophysiology of pressure ulcers. Wound Rep Reg 1995;3:273-83.
30. Grinnell F, Ho C-H, Wysocki AB. Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, immunoblotting, and cell adhesion assays. J Invest Dermatol 1992;98:410-6.
31. Rao CN, Ladin DA, Liu YY, Chilukuri K, Hou ZZ, Woodley DT. α1-antitrypsin is degraded and non-functional in chronic wounds but intact and functional in acute wounds: the inhibitor protects fibronectin from degradation by chronic wound fluid enzymes. J Invest Dermatol 1995;105:572-8.
32. Bullen EC, Longaker MT, Updike DL, Benton R, Ladin D, Hou Z, Howard EW. Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds. J Invest Dermatol 1995;104:236-40.
33. Grinnell F, Zhu M. Fibronectin degradation in chronic wounds depends on the relative levels of elastase, α1-proteinase inhibitor, and α2-macroglobulin. J Invest Dermatol 1996;106:335-41.
34. Stacey MC, Burnand KG, Mahmoud-Alexandroni M, Gaffney PJ, Bhogal BS. Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers. Br J Surg 1993;80:596-9.
35. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
36. Nakajima K, Powers JC, Ashe BM, Zimmerman M. Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. J Biol Chem 1979;254:4027-32.
37. Sottrup-Jensen L. α-Macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 1989;264:11539-42.
38. Barrett AJ, Starkey PM. The interaction of alpha 2-macroglobulin with proteinases: characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J 1973;133:709-24.
39. Remold-O'Donnell E, Nixon JC, Rose RM. Elastase inhibitor. Characterization of the human elastase inhibitor molecule associated with monocytes, macrophages, and neutrophils. J Exp Med 1989;169:1071-86.
40. Kruithof EK. Plasminogen activator inhibitors - a review. Enzyme 1988;40:113-21.
41. Borth W. α2-Macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J 1992;6:3345-53.
42. Sprugel KH, McPherson JM, Clowes AW, Ross R. Effects of growth factors in vivo. I. Cell ingrowth into porous subcutaneous chambers. Am J Pathol 1987;129:601-13.
43. LaMarre J, Wollenberg GK, Gonias SL, Hayes MA. Reaction of α2-macroglobulin with plasmin increases binding of transforming growth factors-β1 and β2. Biochim Biophys Acta 1990;1091: 197-204.
44. Borth W, Luger TA. Identification of α2-macroglobulin as a cytokine binding plasma protein. Binding of interleukin-1b to "F" α2-macroglobulin. J Biol Chem 1989;264:5818-25.
45. Stouffer GA, LaMarre J, Gonias SL, Owens GK. Activated alpha 2-macroglobulin and transforming growth factor-beta 1 induce a synergistic smooth muscle cell proliferative response. J Biol Chem 1993;268:18340-4.
46. Bonner JC, Badgett A, Osornio-Vargas AR, Hoffman M, Brody AR. PDGF-stimulated fibroblast proliferation is enhanced synergistically by receptor-recognized α2-macroglobulin. J Cell Physiol 1990;145:1-8.
47. Wollenberg GK, LaMarre J, Rosendal S, Gonias SL, Hayes MA. Identification of α2-macroglobulin as a carrier of human tumor necrosis factor-α: preferential binding to α2-macroglobulin-plasmin or α2-macroglobulin-methylamine. Am J Pathol 1991;138:265-72.
48. LaMarre J, Wollenberg GK, Gauldie J, Hayes MA. α2-Macroglobulin and serum preferentially counteract the mitoinhibitory effect of transforming growth factor-β2 in rat hepatocytes. Lab Invest 1990;62:545-51.
49. Robson MC, Phillips LG, Heggers JP, McPherson MA, Heiner LS. Clinical studies on growth factors in pressure sores: preliminary report. Prog Clin Biol Res 1991;365:95-102.
50. Mustoe TA, Cutler NR, Allman RM, Goode PS, Deuel TF, Prause JA, Bear M, Serdar CM, Pierce GF. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers. Arch Surg 1994;129: 213-9.
51. Ganio C, Tenewitz FE, Wilson RC, Moyles BG. The treatment of chronic nonhealing wounds using autologous platelet-derived growth factors. J Foot Ankle Surg 1993;32:263-8.
52. Hayward P, Hokanson J, Heggers J, Fiddes J, Klingbeil C, Goeger M, Robson M. Fibroblast growth factor reverses the bacterial retardation of wound contraction. Am J Surg 1992;163:288-93.
53. Falanga V. Growth factors: status and expectations. In: Leaper DJ, editor. International Symposium on Wound Repair. Amsterdam: Medicom Europe BV, 1991:87-93.
54. Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet 1992;339:23-5.
55. Falanga V, Eaglstein WH, Bucalo B, Katz MH, Harris B, Carson P. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. Dermatol Surg Oncol 1992;18:604-6.